Investigation of Differences Between Manufacturers and Public Analyses in Health Technology Assessment in Japan
This study identified key differences and contributing factors under the Japanese HTA system. The findings are expected to inform future refinements of the system and its guidelines, thereby promoting more transparent and predictable evaluations.
Authors
- Yoko Hirano (ORCID: https://orcid.org/0000-0003-2151-2083)
- Akira Yuasa (ORCID: https://orcid.org/0000-0002-3699-7231)
- Hiroshi Nakamura (ORCID: https://orcid.org/0000-0001-7699-9840)
- Kunio Matsumoto (ORCID: https://orcid.org/0000-0002-6532-4482)
Institutions
- Keio University (JP)
- IQVIA (United Kingdom) (GB)
- Pfizer (Japan) (JP)
- IQ Solutions (US)
Publication Details
- Journal
- Journal of health economics and outcomes research
- Published
- 2025-10-31
- DOI
- https://doi.org/10.36469/001c.144530
- Primary Topic
- Health Systems, Economic Evaluations, Quality of Life
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Pfizer
- Pfizer Japan